User: Guest

SUNITINIB MALATE

Global Market Trajectory & Analytics

MCP15073

VALIDATED EXECUTIVE ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

2902

Interactions with Platform & by Email *

INTERACTIONS

522

Unique # Participated *

PARTICIPANTS

87

Responses Validated *

VALIDATIONS

39

* Login to view program details and full enterprise executive list.


  •  DATE

    JULY 2020

  •  TABLES

    32

  •  PAGES

    106

  •  EDITION

    8

  •  PRICE

    USD $4950


COVID-19 IMPACT SURVEY
Amid the COVID-19 crisis, the global market for Sunitinib Malate estimated at US$66.8 Million in the year 2020, is projected to reach a revised size of US$160.8 Million by 2027, growing at a CAGR of 13.4% over the period 2020-2027.
The Sunitinib Malate market in the U.S. is estimated at US$19.7 Million in the year 2020. The country currently accounts for a 29.54% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$28.1 Million in the year 2027 trailing a CAGR of 12.9% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.8% and 11.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.8% CAGR while Rest of European market (as defined in the study) will reach US$28.1 Million by the year 2027.We bring years of research experience to this 8th edition of our report. The 106-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others, Active Biotech AB; Astellas Pharma, Inc.; AstraZeneca PLC; Bristol-Myers Squibb Company; Dendreon Corporation; Endo Pharmaceuticals, Inc.; Ferring Pharmaceuticals, Inc.; Ipsen Pharma; Pfizer, Inc.; Takeda Pharmaceutical Co., Ltd.; Teva Pharmaceutical Industries Ltd.; TOLMAR Pharmaceuticals, Inc.
» Segment (Sunitinib Malate)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

INSIDER ACCESS PRIVILEGES

Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.

  • A: 
    ACTIVE CLIENT
  • B: 
    INACTIVE CLIENT
  • C: 
    ACTIVE PANELIST
  • D: 
    INACTIVE PANELIST
  • E: 
    OPT-INS
  
REPORT INDEX PROJECT COMPENDIUM * EXPERT PANEL

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com